Skip to content

Effects of non-invasive Neuromodulation in the treatment of pain of people with advanced Cancer - a randomized controlled clinical trial focusing on an occupation of daily living

Effects of non-invasive Neuromodulation on pain management in people with advanced Cancer - randomized controlled clinical study focused on a daily life occupation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-28nhd4q
Enrollment
Unknown
Registered
2025-12-11
Start date
2026-02-23
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Interventions

The treatment consists of 10 daily sessions from the first day (considered D.1) to the last day (considered D.10) excluding Saturdays and Sundays, lasting approximately 20 minutes each day. Participan

Sponsors

Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo
Lead Sponsor
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: have a diagnosis of head and neck cancer (of the oral cavity, larynx or pharynx), age between 18 and 75 years and a pain score of at least 4 points on a numerical pain scale (ranging from 0 to 10 points)

Exclusion criteria

Exclusion criteria: Exclusion criteria: pregnancy and intracranial tumor and or metastasis

Design outcomes

Primary

MeasureTime frame
The outcome will be defined by a 3-point reduction in the numerical pain scale between the baseline score recorded on the day of the initial assessment; considered day zero (D.0); and on the tenth day (D.10), which will be the last day of stimulation; on the thirteenth day (D.13); which will be the first reassessment; and on the thirtieth day (D.30); which will be the second reassessment.

Secondary

MeasureTime frame
Assess whether there is any residual effect 20 days after treatment interruption, which will be on day 30 (D.30). The following outcomes will be evaluated: intensity of pain and symptoms such as fatigue, dyspnea, anxiety and perception of depression, amount of analgesics used, quality of life, functional and occupational performance in activities of daily living (oral hygiene)

Countries

Brazil

Contacts

Public ContactMarysia Rodrigues do Prado De Carlo

Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo

marysia@fmrp.usp.br+55 16 99993-3889

Outcome results

None listed

Source: REBEC (via WHO ICTRP)